Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first ...
JERUSALEM, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, ...
Alpha Tau Medical’s proprietary Alpha DaRT device safely delivers alpha radiation with localized precision to treat cancers. Alpha Tau is waiting for FDA feedback to initiate a US pivotal trial in ...
Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission ...
JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, announced today that the FDA ...
An update from Alpha Tau Medical Ltd ( ($DRTS) ) is now available. On January 5, 2026, Alpha Tau Medical announced it has submitted the first ...
Alpha DaRT technology uses diffusing alpha emitters to treat solid tumours. (Courtesy: Alpha Tau Medical) Diffusing alpha-emitters radiation therapy (DaRT) uses interstitial radioactive seeds that ...
Radioactive decay produces three flavors of emissions: alpha, beta, and gamma. Alpha particles comprise 2 neutrons and 2 protons. Because of their large mass and relatively slow speed, alpha particles ...
The top news to come out of skin cancer coverage this year for MHE focused on blood or marrow transplant recipients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback